

Correction to “Disposition and Metabolism of [¹⁴C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans”

In the article referenced above [Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, and Boyle G (2011) *Drug Metab Dispos* **39**:215–227], in *Discussion* (p. 225, second paragraph, line 6), the relative steady-state proportions of the two metabolites are incorrect because of an unfortunate juxtaposition of metabolite nomenclature. The corrected text appears below.

Subsequent analysis of both metabolites (using a validated bioanalytical method) after single and repeat dosing of SB-649868 (once daily) to humans showed accumulation of GSK2329158 (M25) similar to that seen with parent compound (approximately 1.5-fold), whereas GSK2329163 (M98) showed approximately 2- to 3-fold accumulation. The result is that GSK2329158 has systemic exposures of approximately 10% of that of parent compound, whereas GSK2329163 has exposure comparable to that of SB-649868 upon repeat dosing (P. Bettica, A. Lavergne, S. Zamuner, and C. Renzulli, unpublished data).

The online version of this article has been corrected in departure from the print version.

The authors regret this error and apologize for any confusion or inconvenience it may have caused.